Sobi Receives Complete Response Letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

Дата публикации: 26-06-2026 02:06:14

26 June, 2026 -- Sobi® (STO: SOBI) today announced that the Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Company’s Biologics License Application (BLA) for NASP...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA	0	13.35	22-06-2026
2	Camurus Provides Regulatory Update on the US NDA for CAM2029 (Oclaiz™) in Acromegaly	0	13.28	10-06-2026
3	Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD	0	15.69	28-05-2026
4	FDA Grants Fast Track Designation to SOTIO’s SOT109, a CDH17-targeting ADC for Colorectal Cancer	0	17.03	14-07-2026
5	Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy	0	8.22	01-06-2026
6	Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod	0	18.01	30-07-2026
7	Sanofi Announces Decision Not to Submit Amlitelimab in Atopic Dermatitis for Global Regulatory Reviews	0	10.91	24-07-2026
8	Агидель: Ночь 20 дек, Чт	0	0	19-12-2018
9	В Кузнецке прошел городской конкурс «А ну-ка, парни!»	0	0	21-02-2025
10	☝Мамы, хотите действительно отдохнуть и не думать как накормить любимых, ...	5	6	29-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 9.15. Источник: www.drugs.com.